The Pharmacy Times® Cardiovascular Health Resource Center is a comprehensive resource for clinical news and expert insights on the health of the heart and blood vessels, including coronary heart disease, stroke, heart failure, heart arrhythmias, and heart valve issues.
August 25th 2025
Evolocumab is now indicated for adults at increased risk for major adverse cardiovascular events (MACE).
FDA Approves Evinacumab-dgnb for Young Children With Homozygous Familial Hypercholesterolemia
March 22nd 2023Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc) is the first FDA-approved treatment indicated for children as young as 5 years of age to treat dangerously high levels of LDL-C.
Read More
Study: Linking Flu Vaccination, Potential Cardiovascular Benefits Increases Vaccination Rates
March 9th 2023Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.
Read More
ACC 2023 Session Highlights Need for Pharmacists in Cardio-Oncology Care Teams
March 6th 2023Because of the complexities of cardio-oncology medication regimens, pharmacists are vital to assess drug-drug interactions using multiple resources, such as databases, case reports, FDA and National Institutes of Health guidelines, and package inserts.
Read More
Bempedoic Acid Reduces Major Adverse Cardiovascular Events in Patients Who Cannot Tolerate Statins
March 4th 2023Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein-cholesterol.
Read More